Druhá rekurence karcinomu prsu 36 let po počátečním chirurgickém výkonu a 18 let po první rekurenci – extrémně vzácný případ

Stáhnout PDF English version

Autoři: Y. Maezawa ¹; T. Terada ²; H. Kobayashi ²; G. Ohara ¹; T. Saito ³; N. Takayashiki ⁴; H. Satoh ¹
Působiště autorů: Department of Respiratory Medicine, Mito Kyodo General Hospital, Mito, Japan ¹; Department of Internal Medicine, Mito Kyodo General Hospital, Mito, Japan ²; Department of Breast Surgery, Mito Kyodo General Hospital, Mito, Japan ³; Department of Pathology, Mito Kyodo General Hospital, Mito, Japan ⁴
Vyšlo v časopise: Klin Onkol 2026; 39(2): 117-121
Kategorie: Kazuistika
doi: https://doi.org/10.48095/ccko2026117

Souhrn

Východiska: Karcinom prsu patří k nejčastějším příčinám úmrtí na rakovinu na světě. Významnou charakteristikou tohoto onemocnění je pozdní recidiva. Případ: Setkali jsme se s extrémně vzácným případem karcinomu prsu, u kterého došlo k druhé recidivě 36 let po původní operaci a 18 let po první recidivě, projevující se oboustranným pleurálním výpotkem a četnými kostními metastázami. Závěr: Tento článek zdůrazňuje důležitost toho, aby si jak pacienti, tak lékaři uvědomovali, že tyto případy existují.

Klíčová slova:

karcinom prsu – pozdní rekurence – druhá rekurence

--------------

Zdroje

1. Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024; 74 (3): 229–263. doi: 10.3322/caac.21834.

2. Robertson C, Arcot Ragupathy SK, Boachie C et al. The clinical effectiveness and cost-effectiveness of different surveillance mammography regimens after the treatment for primary breast cancer: systematic reviews registry database analyses and economic evaluation. Health Technol Assess 2011; 15 (34): v–vi, 1–322. doi: 10.3310/hta15340.

3. Drukteinis JS, Gombos EC, Raza S et al. MR imaging assessment of the breast after breast conservation therapy: distinguishing benign from malignant lesions. Radiographics 2012; 32 (1): 219–234. doi: 10.1148/rg.321115016.

4. Anderson SJ, Wapnir I, Dignam JJ et al. Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five national surgical adjuvant breast and bowel project protocols of node-negative breast cancer. J Clin Oncol 2009; 27 (15): 2466–2473. doi: 10.1200/JCO.2008.19.8424.

5. Komoike Y, Akiyama F, Iino Y et al. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006; 106 (1): 35–41. doi: 10.1002/cncr.21551.

6. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14 (10): 2738–2746. doi: 10.1200/JCO. 1996.14.10.2738.

7. Takada K, Kashiwagi S, Kawajiri H et al. Late recurrence of breast cancer 32 years after surgery –⁠ a case report. [Japanese]. Gan To Kagaku Ryoho 2004; 31 (4): 678.

8. Yin D, Zhang G, Zhao L et al. Pulmonary resection and systemic lymph node dissection in a patient with breast cancer WHO had a 33-year disease-free interval. World J Surg Oncol 2015; 13 : 150. doi: 10.1186/s12957-015-0565-y.

9. Okutani D, Andou A, Yamadori I et al. Pulmonary metastasis from breast cancer 38 years after mastectomy; report of a case. [Japanese]. Kyobu Geka 2014; 67 (7): 592-594.

10. Tashima Y, Kawano K. A case of local recurrence developing thirty-nine years after mastectomy for breast cancer. [Japanese]. Gan to Kagaku Ryoho 2014; 41 (3): 357-9.

11. Oshima K, Kikumori K, Yanagawa T et al. A case of late recurrence of breast cancer with chest wall recurrence 43 years after surgery. [Japanese]. Gan To Kagaku Ryoho 2021; 48 (13): 1846–1848.

12. Pagani O, Senkus E, Wood W et al. International guidelines for management of metastatic breast cancer: can metastatic breast cancer be cured? J Natl Cancer Inst 2010; 102 (7): 456–463. doi: 10.1093/jnci/djq029.

13. Lim GH, Alcantara VS, Ng RP et al. Patterns of breast cancer second recurrences in patients after mastectomy. Breast Cancer Res Treat 2022; 196 (3): 583–589. doi: 10.1007/s10549-022-06772-4.

14. Wapnir IL, Gelber S, Anderson SJ et al. Poor prognosis after second locoregional recurrences in the CALOR trial. Ann Surg Oncol 2017; 24 (2): 398–406. doi: 10.1245/s10434-016-5571-y.

15. Pedersen RN, Mellemkjær L, Ejlertsen B et al. Mortality after late breast cancer recurrence in Denmark. J Clin Oncol 2022; 40 (13): 1450–1463. doi: 10.1200/JCO.21.02062.

16. Giannakeas V, Narod SA. A generalizable relationship between mortality and time-to-death among breast cancer patients can be explained by tumour dormancy. Breast Cancer Res Treat 2019; 177 (3): 691–703. doi: 10.1007/s10549-019-05334-5.

17. Chen X, Fan Y, Xu B. Distinct characteristics and metastatic behaviors of late recurrence in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer: a single institute experience of more than 10 years. Clin Breast Cancer 2018; 18 (6): e1353–e1360. doi: 10.1016/j.clbc.2018.07.014.

18. Kang Y, Pantel K. Tumor cell dissemination: emerging biological insights from animal models and cancer patients. Cancer Cell 2013; 23 (5): 573–581. doi: 10.1016/j.ccr.2013.04.017.

19. Naumov GN, MacDonald IC, Weinmeister PM et al. Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res 2002; 62 (7): 2162–2168.

20. Ghajar CM, Peinado H, Mori H et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 2013; 15 (7): 807–817. doi: 10.1038/ncb2767.

21. Tjensvoll K, Nordgård O, Skjæveland M et al. Detection of disseminated tumor cells in bone marrow predict late recurrences in operable breast cancer patients. BMC Cancer 2019; 19 (1): 1131. doi: 10.1186/s12885-019-6268-y.

22. Takeuchi H, Tsuji K, Ueo H. Prediction of early and late recurrence in patients with breast carcinoma. Breast Cancer 2005; 12 (3): 161–165. doi: 10.2325/jbcs.12.161.

23. Courdi A, Largillier R, Ferrero JM et al. Early versus late local recurrences after conservative treatment of breast carcinoma: differences in primary tumor characteristics and patient outcome. Oncology 2006; 71 (5–6): 361–368. doi: 10.1159/000107771.

24. van der Sangen MJC, van de Poll-Franse LV, Roumen RMH et al. The prognosis of patients with local recurrence more than five years after breast conservation therapy for invasive breast carcinoma. Eur J Surg Oncol 2006; 32 (1): 34–38. doi: 10.1016/j.ejso.2005.10.005.